RxDoctor Payments Data

Margie Gleason

Family · Las Cruces, NMNPI 1700570801

Payments from drug & device makers

$1,014in general payments, 2019–2025

Across 41 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$348
  • Integra Lifesciences Corporation$155
  • KCI USA, Inc.$151
  • Solventum Corporation$116
  • Organogenesis Inc.$58
  • Tactile Systems Technology Inc$48
  • plus $138 from 7 others

What the payments were for

  • Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,014 in reported general payments places this provider in the 75th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$535,533
Medicare patients
165
Services billed
3,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.42$30,089
Linezolid35$3,547
Mupirocin111$1,322
Gentamicin Sulfate24$893
Triamcinolone Acetonide47$620
Doxycycline Hyclate23$369
Cephalexin29$306
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$225
Levofloxacin29$173
Fluconazole17$113
Gabapentin11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$348$30,08942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →